Title
Category
Credits
Event date
Cost
  • S.U.D
  • AAFP Prescribed
  • AMA PRA Category 1 Credit™
  • AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
  • S.U.D
  • AAFP Prescribed
  • AMA PRA Category 1 Credit™
  • AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, participants should be able to:
  • S.U.D
  • AAFP Prescribed
  • AMA PRA Category 1 Credit™
  • AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • AAFP Prescribed
  • AMA PRA Category 1 Credit™
  • AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • AAFP Prescribed
  • AMA PRA Category 1 Credit™
  • AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • AAFP Prescribed
  • AMA PRA Category 1 Credit™
  • AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • AAFP Prescribed
  • AMA PRA Category 1 Credit™
  • AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:After this course, participants should be able to:
  • S.U.D
$0.00
These activities are part of the education provided for the California Residency Program Collaborative (CRPC) and available to the general public to improve education, outreach, and treatment for patients with Substance Use Disorder (SUD), including stimulant use disorder, and opioid use disorder with a focus on increasing capacity for effective Medication Assisted Treatment (MAT) implementation. Some of the activities will be accredited for CME. For more information, go to www.familydocs.org/crpc.
$0.00
Interview season is just around the corner! Program Directors, faculty, residents and staff will be focused on assessing and recruiting the best trainees for their programs. With that, let's take a look at strategies to remove bias from the recruitment process as well as in medical education.
$0.00
This course was originally presented at the 2020 Family Medicine Clinical Forum and offered separately here for free without accreditation. We will discuss how racism appears in medical research, education and clinical practice and identity actions of anti-racism and allyship that can be executed at individual, interpersonal, and structural levels.UNLABELED USE DISCLOSUREThis activity will not include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), and the curriculum clearly indicates this fact.

Pages